Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-43366

Kaiser, P R; Valko, P O; Werth, E; Thomann, J; Meier, J; Stocker, R; Bassetti, C L; Baumann, C R (2010). Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology, 75(20):1780-1785.

Published Version
View at publisher


BACKGROUND: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue.

METHODS: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (questionnaires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomotor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients were treated with placebo. After a 6-week treatment period, all examinations were repeated.

RESULTS: EDS improved significantly in patients with TBI who were treated with modafinil, compared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakefulness test improved only in the modafinil group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed.

CONCLUSION: This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that modafinil (100-200 mg daily) improves posttraumatic EDS compared with placebo. This study provides Class I evidence that modafinil (100-200 mg daily) does not improve posttraumatic fatigue compared with placebo.


43 citations in Web of Science®
50 citations in Scopus®
Google Scholar™



3 downloads since deposited on 26 Jan 2011
2 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Deposited On:26 Jan 2011 18:04
Last Modified:05 Apr 2016 14:39
Publisher:American Academy of Neurology
Additional Information:Comment in: Neurology. 2010 Nov 16;75(20):1764-5.
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1212/WNL.0b013e3181fd62a2
PubMed ID:21079179

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page